Lumida
/COGT
⌘K
Cogent Biosciences Inc

Cogent Biosciences Inc

COGT
$33.41USD-1.97%-0.67 today

MARKET CAP

5.8B

P/E (TTM)

FWD P/E

DAY RANGE

$33 – $35

52W RANGE

$12
$44

AI Summary

Stalk
Sell NowMedium

COGT is in Stage 3 distribution after a decisive support failure and Bearish Pivot Point, establishing a bearish medium-term bias. Price trades below declining EMAs and rejects rallies into the 9/20 EMA region, justifying immediate sell-side engagement. Extreme oversold conditions introduce risk of a relief bounce, but the downtrend remains intact until key support breaks.

  • Phase 3 PEAK trial showed 50% lower progression risk.
  • Three NDAs pending; two under FDA priority review late 2026.
  • Q2 ’26 net loss $96.4M (+31.7% YoY); profitability remains negative.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020TREND
Sales, Adj.$7.9M
YoY %
P / Sales15.8x
EV / Sales-12.9x
Gross Profit, Adj.$7.9M
YoY %
Margin %100.0%
EV / Gross Profit-12.9x
EBITDA, Adj.$-81.5M
YoY %
Margin %-1035.2%
EV / EBITDA1.2x
EBIT$-82.2M
YoY %
Margin %-1044.3%
EV / EBIT1.2x
Net Income$-179.2M
YoY %
Net Margin-2276.8%
EPS (GAAP)-$16.17
YoY %